Related Experiment Video
Updated: Apr 29, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Current treatment guidelines for chronic hepatitis B and their applications
Lindsay A Uribe1, Connor G O'Brien, Robert J Wong
1*Department of Medicine, Stanford University Medical Center †Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto ‡Division of Gastroenterology and Hepatology, University of California, San Diego, CA §School of Medicine, University of Hawaii, Honolulu, HI.
Managing chronic hepatitis B (CHB) requires understanding host and viral factors to prevent severe liver disease. Guidelines offer a framework, but improved education and noninvasive markers are crucial for optimal patient selection and treatment.
Area of Science:
- Hepatology
- Virology
- Clinical Medicine
Background:
- Chronic hepatitis B (CHB) management guidelines vary globally.
- Several professional associations provide treatment recommendations for CHB.
- This review compares major international CHB treatment guidelines.
Purpose of the Study:
- To review CHB management principles.
- To systematically summarize and compare key international treatment guidelines.
- To identify areas for improved patient care and risk stratification.
Main Methods:
- Recommendations were analyzed for hepatitis B e antigen (HBeAg)-positive patients.
- Recommendations were analyzed for HBeAg-negative patients.
- Comparative analysis of guidelines from major liver associations.
Main Results:
- Treatment decisions for CHB depend on host and viral factors.
- The primary goal of CHB treatment is to prevent liver decompensation, cirrhosis, hepatocellular carcinoma, and premature death.
- Current guidelines have improved over the past decade.
Conclusions:
- Enhanced patient and physician education is needed for CHB management.
- Development of better noninvasive markers is required to identify high-risk CHB patients.
- Future molecular and genomic techniques may improve high-risk patient selection for CHB treatment.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Inhibitors of Viral Protein Synthesis
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...